1 Department of Otolaryngology, University of Alabama at Birmingham, Birmingham, Alabama, USA.
2 Center for Clinical and Translational Science, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Otolaryngol Head Neck Surg. 2018 Jul;159(1):68-75. doi: 10.1177/0194599818756617. Epub 2018 Feb 13.
Objective The Surgical Apgar Score (SAS) is a validated postoperative complication prediction model. The purpose of this study was to investigate the utility of the SAS in a diverse head and neck cancer population and to compare it with a recently developed modified SAS (mSAS) that accounts for intraoperative transfusion. Study Design Case series with chart review. Setting Academic tertiary care medical center. Subjects and Methods This study comprised 713 patients undergoing surgery for head and neck cancer from April 2012 to March 2015. SAS values were calculated according to intraoperative data obtained from anesthesia records. The mSAS was computed by assigning an estimated blood loss score of zero for patients receiving intraoperative transfusions. Primary outcome was 30-day postoperative morbidity. Results Mean SAS and mSAS were 6.3 ± 1.5 and 6.2 ± 1.7, respectively. SAS and mSAS were significantly associated with 30-day postoperative morbidity, length of stay, operative time, American Society of Anesthesiologists status, race, and body mass index ( P < .05); however, no significant association was detected for age, sex, and smoking status. Multivariable analysis identified SAS and mSAS as independent predictors of postoperative morbidity, with the mSAS ( P = .03) being a more robust predictor than the SAS ( P = .15). Strong inverse relationships were demonstrated for the SAS and mSAS with length of stay and operative time ( P < .0001). Conclusion The SAS serves as a useful metric for risk stratification of patients with head and neck cancer. With the inclusion of intraoperative transfusion, the mSAS demonstrates superior utility in predicting those at risk for postoperative complications.
手术 Apgar 评分(SAS)是一种经过验证的术后并发症预测模型。本研究旨在探讨 SAS 在不同头颈部癌症人群中的应用,并将其与最近开发的考虑术中输血的改良 SAS(mSAS)进行比较。
病例系列,病历回顾。
学术性三级保健医疗中心。
本研究纳入了 2012 年 4 月至 2015 年 3 月期间因头颈部癌症接受手术的 713 例患者。SAS 值根据麻醉记录中的术中数据计算得出。mSAS 通过对接受术中输血的患者分配零估计失血量评分来计算。主要结局为术后 30 天的发病率。
平均 SAS 和 mSAS 分别为 6.3±1.5 和 6.2±1.7。SAS 和 mSAS 与术后 30 天发病率、住院时间、手术时间、美国麻醉医师协会状态、种族和体重指数显著相关(P<0.05);然而,年龄、性别和吸烟状况与两者均无显著相关性。多变量分析确定 SAS 和 mSAS 是术后发病率的独立预测因素,mSAS(P=0.03)比 SAS(P=0.15)更具预测价值。SAS 和 mSAS 与住院时间和手术时间呈显著负相关(P<0.0001)。
SAS 是头颈部癌症患者风险分层的有用指标。通过纳入术中输血,mSAS 在预测术后并发症风险方面具有更好的应用价值。